Thea Supplement: Use of Intracameral Cefuroxime

In 2007, results from the ESCRS Endophthalmitis Prophylaxis Study showed that intracameral cefuroxime significantly reduced the risk of endophthalmitis after cataract surgery [ESCRS Endophthalmitis Study Group. J Cataract Refract. Surg. 2007;33:978-988]. Then in 2012, a major obstacle to systematic intracameral use was eliminated when Aprokam® (cefuroxime 50mg powder for injection; Laboratoires Théa) was approved across Europe as the first and only product indicated for intracameral administration to prevent endophthalmitis after cataract surgery. As of September, 2014, this single-use agent is available in 23 European countries, with approval being sought elsewhere around the world. Download Supplement

Latest Articles

Thinking Beyond Optics: Diversity, Equity, and Inclusion (DEI) and Unconscious Bias in Ophthalmology

Beyond Sight: A Clearer Vision for Equity in Ophthalmology

Refractions of Bias: Seeing DEI Clearly in Ophthalmology

Happy Patients, Higher Volumes

Digitalisation reduces errors and saves time, making a surgeon’s life easier.

Addressing Postoperative Visual Complications

Managing aberrations after laser refractive surgery requires a multi-layered approach.

3D Printing Helps Transform Ukrainian Eye Care

The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.

Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation

Emerging Microbial Trends That Could Affect Your Practices

A triptych of challenges paints a concerning picture for ophthalmologists across the globe.

Improving Outcomes with Laser-Assisted Surgery

Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.

Could the Corneal Transplant Pool Increase?

Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.